JPRN-UMIN000005352已完成2 期
A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia. - A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Severe comorbidity (infection, lung disease, hypertension, heart failure, diabetes mellitus) 2.Recent history of ischemic heart disease 3.Other active neoplasms 4.Pregnant and/or lactating woman 5.Psychological disorders 6.Positive HBs antigen and/or anti-HIV antibody 7.Received allogeneic stem cell transplantation within 100 days 8. Receiving immunosuppressive agents (cyclosporine, tacrolimus)
研究者
相似试验
已完成
2 期
Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaLeukemia, PediatricNCT01460160Bristol-Myers Squibb106
撤回
1 期
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT02680951Emory University
已完成
2 期
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.BCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic Leukemiat(9;22)Acute Lymphoblastic LeukemiaNCT00390793M.D. Anderson Cancer Center107
进行中（未招募）
2 期
ALL-Ph18Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaJPRN-jRCTs041190067Shimada Hiroyuki57
进行中（未招募）
不适用
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-BEBristol-Myers Squibb International Corporation300